Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | MGAT2 | Q10469 | 10/20 | 0.35 |
| ▸ | MGAT1 | P26572 | 4/20 | 0.35 |
| ▸ | MGAT3 | Q09327 | 3/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13382919 | 0.80 | MGAT2 (0.40) | HTR6MGAT2BRD4APPMAPT | |
| SCHEMBL13382910 | 0.71 | GAA (0.43) | MAPT | |
| SCHEMBL13545311 | 0.70 | HTR6 (0.34) | HTR6MGAT2 | |
| SCHEMBL23346087 | 0.69 | — | — | |
| SCHEMBL13545349 | 0.68 | PDK2 (0.52) | HTR6 | |
| SCHEMBL14566623 | 0.68 | PDK2 (0.52) | — | |
| SCHEMBL13382920 | 0.65 | HTR6 (0.38) | HTR6BRD4MAPT | |
| SCHEMBL13545259 | 0.65 | KDM4E (0.56) | BRD4 | |
| SCHEMBL13382908 | 0.64 | SMYD3 (0.43) | APPMAPT | |
| SCHEMBL27464267 | 0.64 | HTR6 (0.37) | HTR6NQO2APPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | HTR6 1987/4885MGAT2 1988/4885MGAT1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.